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ABSTRACT
The standard therapy for some autoimmune diseases consists of a combination of corticosteroids and thiopurines. 
In non-responders to thiopurine drugs, the measurement of the metabolites of azathioprine, 6-thioguanine, and 
6-methylmercaptopurine, can be a useful tool. The measurement has been used during the treatment of inflammatory 
bowel diseases and, less commonly, in autoimmune hepatitis. Many patients preferentially metabolize thiopurines 
to 6-methylmercaptopurine (6-MMP), which is potentially hepatotoxic, instead of 6-thioguanine, the active 
immunosuppressive metabolite. The addition of allopurinol shifts the metabolism of thiopurine towards 6-thioguanine, 
improving the immunosuppressive effect. We present the case of a 51-year-old female with autoimmune hepatitis 
who had a biochemical response after azathioprine and prednisone treatment without histological remission, and who 
preferentially shunted to 6-MMP. After the addition of allopurinol, the patient’s 6-thioguanine levels increased, and she 
reached histological remission with a reduction of 67% of the original dose of azathioprine. The patient did not develop 
clinical manifestations as a consequence of her increased immunosuppressive state. We also review the relevant literature 
related to this issue. In conclusion, the addition of allopurinol to thiopurine seems to be an option for those patients who 
do not reach histological remission and who have a skewed thiopurine metabolite profile. 
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INTRODUCTION
The current therapy of autoimmune hepatitis 
(AIH) consists  of cort icosteroids (prednisone 
[PD]/prednisolone) as monotherapy or,  more 
commonly, in combination with azathioprine 
(AZA), and both have similar response rates. In the 
combined therapeutic regimen, the starting dose of 
PD is usually 30 mg/day together with 50 mg/day 
AZA. This regimen has fewer side effects when 
compared with PD alone (10% vs. 44%).1 During the 
treatment, the dose of corticosteroid is continuously 
tapered, whereas the dose of AZA is increased, with 
the final doses varying from 5 mg to 15 mg, and 
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50 mg to 150 mg (1-2 mg/kg/day), respectively.2,3 
Despite the therapy, 9% of patients show clinical 
deterioration, and even with adequate adherence, 
13% exhibit only a partial response, while in 
approximately 10–20% of cases, AZA is poorly 
tolerated because of its side effects.2
AZA is metabolized through three metabolic 
enzymatic pathways: (i) xanthine oxidase, which 
releases an inactive metabolite, thiouric acid; 
(ii) hypoxanthine phosphoribosyl transferase, which 
produces 6-thioguanine (6-TGN), which is responsible 
for the immunosuppressive effect and for myelotoxicity; 
and (iii) thiopurine methyltransferase (TPMT), which 
releases 6-methylmercaptopurine (6-MMP), which may 
account for hepatotoxicity if the levels are higher than 
5,700 pmol/8 × 108 red blood cells (RBC).4-7 The levels 
of 6-TGN between 235 and 450 pmol/8 × 108 RBC are 
considered suitable for immunosuppression without 
presenting marked myelotoxicity.8 The variation of 
the enzyme activity of TPMT in the population can 
be a factor responsible for AZA toxicity. While 89% 
of Caucasians have normal or high TPMT activity, 
6-11% have intermediate activity, and 0.3% have 
insignificant activity, with higher risks of myelotoxicity 
secondary to the metabolic deviation towards the 
hypoxanthine phosphoribosyl transferase pathway.9 
Conversely, for those patients who preferentially 
metabolize thiopurine to 6-MMP instead of 6-TGN, 
AZA can induce hepatotoxicity, usually when the 
levels are higher than 5,700 pmol/8 × 108 RBC.10 
In this situation, the addition of allopurinol shifts the 
metabolism of thiopurine towards 6-TGN, improving 
the immunosuppressive effect of AZA and allowing a 
reduction in its dose. In the medical literature, there 
are few reported cases in which this approach was 
performed in AIH.
This is the report of a 51-year-old female with AIH, 
with only a biochemical response with PD and AZA, 
who had never achieved histological remission. After 
initiating allopurinol, the 6-TGN levels increased, the 
6-MMP reduced, and the patient reached histological 
remission with the same dose of PD and one-third of 
the AZA dose before allopurinol was used. Relevant 
publications with a similar approach in AIH are 
discussed, but it is important to note that this is the 
first case reported in AIH with histological remission 
proven by liver biopsy.
CASE REPORT
A 51-year-old female patient sought medical 
care complaining of pruritus and progressive jaundice 
over the last 5 months. Her medical history included 
hypertension, dyslipidemia, and type 2 diabetes mellitus. 
She had been regularly taking glibenclamide, acetyl 
salicylic acid, omeprazole, and losartan. She denied 
the consumption of alcohol, tobacco, or illicit drugs. 
The physical examination depicted jaundice and mild 
edema in the lower extremities. Initial laboratory 
tests showed total bilirubin 16.1 mg/dL (reference 
range [RR]: <1.2 mg/dL), direct bilirubin 12.4 mg/dL 
(RR: <0.35 mg/dL); international normalized ratio 
(INR) 1.6; aspartate aminotransferase (AST) 1,379 U/L 
(RR: <31 U/L); alanine aminotransferase (ALT) 712 
(RR: <31 U/L); alkaline phosphatase (ALP) 165 U/L 
(RR: <104 U/L); gamma glutamyl transferase (GGT), 
154 U/L (RR: <36 U/L); albumin, 1.8 g/dL (RR: 3.2-5.4 g/dL); 
creatinine, 0.7 mg/dL (RR: 0.6-1.2 mg/dL); hemoglobin 
(Hb) 11.3 g/dL (RR: 12-16 g/dL); platelets 143,000/m3 
(RR: 140,000-450,000 cells/mm3). The serological 
screening for hepatitis A, B, and C viruses was 
negative. She had normal levels of alpha-1-antitrypsin, 
ceruloplasmin, total serum copper, ferritin, and transferrin 
saturation index. She had hypergammaglobulinemia, 
4.47 g/dL (RR: 0.7-1.5 g/dL); elevated immunoglobulin 
G, 5,361 mg/dL (RR: 952-1,538 mg/dL); ≥1/320 
reactivity for both antinuclear antibodies with a 
homogeneous pattern, and for anti-smooth muscle 
antibodies with a tubular pattern (reactivity in vessel 
walls, glomeruli, and fibrils of tubular cells); and 
reactivity for anti-soluble liver antigen/liver pancreas 
antibodies (anti-SLA/LP) using ELISA. The abdominal 
computed tomography imaging revealed signals of 
chronic liver disease; the upper digestive endoscopy 
examination did not show esophageal varices; and the 
liver biopsy revealed portal expansion by fibrosis with 
porto-portal septa, mononuclear infiltrate with plasma 
cell predominance, and severe interface activity, with 
a METAVIR score of F2A3.
The diagnosis was definite AIH using both score 
systems of the International Autoimmune Hepatitis 
Group (IAIHG),11,12 and the combined therapy with PD 
30 mg/day with AZA 50 mg/day was started. The AZA 
dosage was increased until 125 mg/day (1.8 mg/kg/day) 
was reached and PD was tapered off until 10 mg/day 
was reached. After 1 year, ursodeoxycholic acid 
900 mg/day was introduced because of the abnormal 
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levels of GGT and ALP, which reached nine and two 
times the normal values, respectively. In the third 
year of follow-up, the patient was asymptomatic 
and finally achieved biochemical remission, with 
the normalization of aminotransferase levels. After 
18 months of normalized hepatic enzymes, she 
underwent another liver biopsy to evaluate histological 
remission. However, the histological report showed 
moderate fibrosis and discrete periportal activity with 
an inflammatory infiltrate still rich in plasma cells, 
with a METAVIR score of F2A2, and an absence of 
histological remission (Figure 1).
The dosages of AZA and PD were raised to 
150 mg/day (2.1 mg/kg/day) and 12.5 mg/day, 
respectively, and after 18 months another liver 
biopsy was performed. The histological examination 
revealed periportal activity, without plasma cells, and 
progression of fibrosis to F3 (Figure 2).
At this time, the measurement of AZA metabolites 
revealed 6-MMP levels of 11,606 pmol/8 x 108 RBC, 
which were higher than the threshold for hepatotoxicity; 
and 6-TGN of 378 pmol/8 x 108 RBC. Since the levels 
of 6-MMP were very high, AZA was reduced to 
75 mg/day, PD was maintained at 12.5 mg/day, and 
allopurinol 100 mg/day was added to the therapeutic 
regimen. Four months later, the levels of 6-MMP 
were 9,655 pmol/8 × 108 RBC and those of 6-TGN 
were 1,498 pmol/8 × 108 RBC. The AZA dosage was 
reduced to 50 mg/day because the 6-TGN levels were 
very high, with a risk for myelotoxicity. The patient had 
no allopurinol adverse effects, and no manifestations 
of hyper immunosuppression. After 4 years under 
this new therapeutic regimen, another liver biopsy 
was performed, with fibrosis stage F3, and minimal 
periportal activity (only spill-over of lymphocytes 
beyond the interface of portal tracts to the liver 
parenchyma), in a healing pattern, with a METAVIR 
score of F3A1 and an Ishak’s histological activity index 
(HAI) of 3, which was compatible with histological 
remission (Figure 3). The patient provided written 
Figure 1. Photomicrography of the liver biopsy performed 
after 18 months of normal levels of aminotransferases. 
A - Persistence of periportal activity with a mononuclear 
inflammatory infiltrate (H&E, 300X); B - Presence of 
plasma cells (arrowhead) (H&E, 700X).
Figure 2. Photomicrography of the liver biopsy 
undertaken when the patient was under the maximum 
dose of azathioprine (2.1 mg/kg/day). Note the lack 
of histological remission. A - Periportal activity with 
inflammatory infiltrate (H&E, 200X); B - Liver fibrosis 
with multiple septa-METAVIR fibrosis stage F3 (Reticulin, 
50X).
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informed consent to the use of allopurinol and to have 
this information published.
DISCUSSION
This patient had a definite diagnosis of AIH 
according to both the classical and the simplified criteria 
of IAIHG, with a final score of 20 and 7 before treatment, 
respectively.11,12 The first goal in the treatment of 
AIH is to reach the complete biochemical response, 
which means the normalization of aminotransferase 
levels, regardless of the period of time that it takes 
for the patient to achieve this result. The next step 
is to reach a complete histological remission, which 
has a less precise definition. The British Society of 
Gastroenterology Guidelines suggest that histological 
resolution correlates with long-term survival, with 
an optimal outcome associated with Ishak’s HAI of 
3 or less.13 In our hospital, we follow the instructions 
of the IAIHG, which considers histological remission 
to be when periportal activity is minimal or absent 
(only a spill-over of chronic inflammatory cells 
beyond the limits of the portal tracts or septa to 
the liver parenchyma).11,14 For this reason, the liver 
biopsy is the only reliable criterion that allows the 
definition of a complete response to treatment of 
AIH. However, we can state that, despite a persistent 
biochemical remission, the full therapeutic response 
with histological remission was not obtained.
In this case, although the biochemical response 
was achieved with the combined therapy of PD 10 mg, 
AZA 125 mg, and ursodeoxycholic acid 900 mg, the 
histological remission was not achieved even with the 
maximum dosage of AZA (150 mg; 2.1 mg/kg/day) 
plus prednisone 12.5 mg/day and ursodeoxycholic 
acid 900 mg/day. In this situation, there were other 
possibilities to follow, such as increasing the dose of 
prednisone. This option was immediately rejected 
because of the patient’s comorbidities, namely: arterial 
hypertension, dyslipidemia, and type 2 diabetes 
mellitus. Another possibility was adding another 
immunosuppressant to the treatment regimen, such as 
a calcineurin inhibitor like cyclosporine or tacrolimus, 
but this option was not adopted because the patient 
was already under treatment for arterial hypertension 
and type 2 diabetes mellitus. The same schedule could 
have been maintained, but this would have precluded 
the possibility of reaching the histological remission 
and any possible subsequent attempt towards 
treatment withdrawal.
Although some authors have demonstrated a 
weak or no relationship between thiopurine metabolite 
levels and therapeutic efficacy or toxicity in patients 
with inflammatory bowel diseases,8 the current concept 
is that patients in remission probably have higher 
6-TGN levels; that is, above 230-260 pmol/8 × 108 RBC. 
The levels of 6-TGN, surprisingly, showed that the 
patient was not as immunosuppressed as could be 
imagined, even though AZA was being used at a 
dosage of 2.1 mg/kg/day. In addition, the measurement 
of the levels of metabolites showed that the patient 
had a good adherence to the treatment. However, the 
possibility of increasing the dose of AZA was promptly 
rejected because the levels of 6-MMP were in the range 
of hepatotoxicity.
Figure 3. Photomicrography of the liver biopsy after the 
reduction of the azathioprine dose, and the addition 
of allopurinol to the prescription. A - Mild periportal 
activity, with only a spill-over of lymphocytes beyond 
the interface of the portal tract to the liver parenchyma 
(H&E, 100X); B - METAVIR fibrosis stage F3 in regression, 
with perforated septa (Sirius red stain, 50X).
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The first study about thiopurine metabolites in 
AIH was performed in pediatric patients in 2002. 
In this population, the measurement of metabolites 
was useful in identifying toxicity, but not adherence 
to therapy.15 Moreover, the correlation between 
metabolite levels and therapeutic response in AIH is not 
well established, with a great variation in metabolite 
levels and biochemical response. In a 2010 study,16 
among the patients who achieved remission, 74% 
had 6-TGN above the therapeutic levels. In that study, 
the histological remission was not evaluated. Another 
study published in 2012 by Dhaliwal et al.,17 showed 
a positive correlation between high levels of 6-MMP 
and cholestasis, and a negative correlation between 
6-TGN levels and ALT. In that study, the therapeutic 
levels of 6-TGN to achieve biochemical remission were 
above 220 pmol/8 × 108 RBC. The biochemical relapse 
occurred more frequently in patients with 6-TGN levels 
below 177 pmol/8 × 108 RBC.
Taking into account the adverse effects of the 
AZA metabolites, another therapeutic possibility 
could be replacing AZA with mycophenolate, which 
has a different mechanism of action. Although the 
latter interferes with the metabolism of thiopurines 
by inhibiting the enzyme inositol monophosphate 
dehydrogenase, this mechanism is quite different 
from AZA and 6-mercaptopurine.18 However, the 
administration of alternative drugs is not fully available 
as a therapeutic option for AIH in the Brazilian Public 
Health Service. The administration of allopurinol in this 
situation seemed suitable because it would be possible 
to increase the levels of immunosuppressive metabolites 
and to reduce those related to hepatotoxicity.
The reason why the levels of 6-TGN increase and 
those of 6-MMP decrease is not completely understood. 
The initial hypothesis was that allopurinol inhibits 
TPMT, which was not evidenced in vitro. The most 
convincing explanation is, that after the introduction 
of azathioprine, there is an induction in up to 92% of 
TPMT synthesis, and with the addition of allopurinol 
and the reduction of azathioprine, a move towards 
6-TGN occurs due to inhibition of xanthine oxidase, 
with a concomitant reduction in TPMT activity.19 
Another possibility is that TPMT may be inhibited by 
metabolites of oxypurinol (the inhibitor of xanthine 
oxidase), such as 6-thioinosine monophosphate, an 
analogue of the TPMT substrate.20,21
The first clinical experiment involving the addition 
of allopurinol to the AZA regimen was in renal 
transplant patients.22 Following this study, this 
association was tested in patients with inflammatory 
bowel diseases who were non-responders to AZA or 
to 6-mercaptopurine. In these patients, the dose of 
AZA was reduced to 25–50% of the original dose, 
and allopurinol 100 mg/day was introduced, which 
led to a significant increase in 6-TGN and a reduction 
of 6-MMP levels, with subjective clinical improvement 
that allowed the interruption of corticosteroid in some 
patients.23
The first experience with allopurinol in patients 
with AIH was in three case reports that overlapped with 
primary sclerosing cholangitis who exhibited elevation 
of aminotransferases due to toxicity by 6-MMP, which 
was reversed after the addition of allopurinol and 
a reduction in the dose of thiopurine, resulting in 
biochemical remission.24 More recently, de Boer et al.25 
published a study with eight patients classified as 
non-responders or as intolerant to therapy who had 
unfavorable thiopurine metabolism. They added 
allopurinol 100 mg/day to 25–33% of the initial 
thiopurine dose, reaching a biochemical improvement 
and showing the possibility of a reduction in the 
corticosteroid dose, and the collateral effects of 
thiopurine. The mean levels of 6-TGN increased from 
100 to 200 pmol/8 × 108 RBC and the mean levels of 
6-MMP reduced from 6,090 to 175 pmol/8 × 108 RBC.25 
In this study, histological remission was not assessed, 
and the hematological effects of thiopurine drugs were 
not significant. There are other isolated case reports 
on the addition of allopurinol in AIH patients, but the 
histological remission was not evaluated.5 In the present 
case, there was a marked elevation in 6-TGN levels and 
a less impressive reduction of 6-MMP, but the patient 
had no clinical signs of excessive immunosuppression, 
myelosuppression, or hepatotoxicity.
Patients with refractory AIH evolve with the 
maintenance of liver inflammation, progressing to 
cirrhosis and portal hypertension. Increasing the 
dose of corticosteroids or AZA may not always 
be the best strategy for these patients because of 
their inherent side effects. The addition of another 
immunosuppressive also may be deleterious because 
other side effects are implicit with them. In these 
situations, the detection of an unfavorable profile of 
thiopurine metabolites can be an opportunity to add 
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allopurinol with a lower dose of the thiopurine drug, 
which shifts the thiopurine metabolism towards 6-TGN, 
thus improving the immunosuppression and decreasing 
the 6-MMP levels, with lower hepatotoxicity. Our case 
is different from those that have been published, 
because the patient did not present the side effects 
of the thiopurine and could not be classified as 
having refractory AIH. The problem was that the 
patient did not achieve histological remission with the 
conventional therapeutic regimen—even when using 
the maximum dose of AZA and an appropriate dose 
of corticosteroids. The addition of allopurinol to the 
therapeutic regimen led to a histological remission with 
a small dose of AZA, which has not yet been described 
in the literature. The possibility of using this low dose 
is interesting because of the reduction in the risk of 
hepatotoxicity, and the likely reduction in the cost of 
treatment.
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ABBREVIATIONS
6-MMP = 6-methylmercaptopurine
6-TGN = 6-thioguanine
AIH = autoimmune hepatitis
ALP = alkaline phosphatase
ALT = alanine aminotransferase
ANA = antinuclear antibodies
anti-SLA/LP = anti-soluble liver antigen/liver pancreas antibodies
ASMA = anti-smooth muscle antibodies
AST = aspartate aminotransferase
AZA = azathioprine
GGT = gamma glutamyl transferase
HAI = Ishak’s histological activity index.
Hb = hemoglobin
IAIHG = International Autoimmune Hepatitis Group
INR = international normalized ratio
PD = prednisone
RBC = red blood cells
TPMT = thiopurine methyltransferase
